Overview

The National Health Reform Act 2011 was enacted to facilitate improvements in the Australian health system, particularly through the establishment of the Independent Hospital Pricing Authority. The Act aimed to address the need for more accurate and consistent pricing of healthcare services, which would contribute to better financial planning and efficiency in the health sector. This legislation was enacted by the Parliament of Australia, reflecting a commitment to reform and enhance the quality and sustainability of healthcare services across the nation. The policy objective of the Act is to ensure that healthcare services are priced in a manner that reflects their true cost, thereby promoting transparency and fairness in the health system. This was intended to support the broader goals of the National Health Reform Agreement, which seeks to improve the overall performance and sustainability of the Australian health system.

Scope and Application

The National Health Reform Act 2011 applies to the Independent Hospital Pricing Authority, which is tasked with determining the national efficient price for health care services provided by public hospitals, particularly where those services are funded on an activity basis. This Act operates under the Commonwealth jurisdiction and extends its reach to all public hospitals within Australia. The Act does not specify particular exclusions or exemptions, but it does clarify that any direction made by the Minister for Health and Ageing must be of a general nature and cannot involve altering specific national efficient prices or efficient costs for hospital services. The Act allows for the Minister to issue directions to the Pricing Authority concerning the performance of its functions and powers, subject to consultation with the Standing Council on Health. This legislative instrument, made under subsection 226(1) of the Act, directs the Pricing Authority to consider actual clinical trial activities and cost-recovery principles when determining the national efficient price for standard clinical trial items. The instrument is not subject to disallowance under the Legislative Instruments Act 2003 and does not require a statement of compatibility with human rights as it does not fall under the purview of the Human Rights (Parliamentary Scrutiny) Act 2011.

Key Provisions

The primary operative sections of the National Health Reform Act 2011, specifically as directed by the Explanatory Statement, focus on the role and functions of the Independent Hospital Pricing Authority (the Pricing Authority). Section 131 of the Act outlines the Pricing Authority's functions, which include determining the national efficient price for healthcare services provided by public hospitals, particularly those funded on an activity basis (s 131(1)(a)). The Explanatory Statement directs the Pricing Authority to determine the national efficient price for a list of standard items associated with conducting clinical trials in Australia (s 131(1)(a)). This determination will aid in assessing the true cost of clinical trial activity, providing valuable insights for clinical trial sponsors and public institutions planning future trials. The Act imposes obligations on the Pricing Authority to comply with the directions given by the Minister under subsection 226(1), which must be of a general nature and cannot direct a particular change in national efficient price or efficient cost for healthcare services (s 226(3)). The Minister is required to consult with the Standing Council on Health before issuing such a direction (s 226(2)). The Pricing Authority is mandated to consider the actual activity of a standard clinical trial item and cost-recovery principles in determining the national efficient price (s 226(4)). This ensures that the Pricing Authority’s decisions are informed by comprehensive and relevant data. Any breaches of the obligations set forth in the Act can result in legal consequences. While the Explanatory Statement does not detail specific offences or penalties, it is understood that non-compliance with directions given under subsection 226(1) could lead to legal action against the Pricing Authority for failing to adhere to ministerial directives. However, the maximum penalties for such breaches are not specified within the document. The legislative framework ensures that the Pricing Authority operates within the scope defined by the Act, maintaining the integrity and purpose of the clinical trial pricing determination process.